PTKFF Financial Statements From 2010 to 2024
| PTKFF Stock | USD 0.1 0.00 0.00% |
Check PT Kalbe financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among PT Kalbe's main balance sheet or income statement drivers, such as , as well as many indicators such as . PTKFF financial statements analysis is a perfect complement when working with PT Kalbe Valuation or Volatility modules.
PTKFF |
PT Kalbe Farma Company Return On Equity Analysis
PT Kalbe's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current PT Kalbe Return On Equity | 0.17 |
Most of PT Kalbe's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PT Kalbe Farma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, PT Kalbe Farma has a Return On Equity of 0.1673. This is 100.7% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The return on equity for all United States stocks is 153.97% lower than that of the firm.
PT Kalbe Farma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining PT Kalbe's current stock value. Our valuation model uses many indicators to compare PT Kalbe value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PT Kalbe competition to find correlations between indicators driving PT Kalbe's intrinsic value. More Info.PT Kalbe Farma is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.63 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for PT Kalbe Farma is roughly 1.58 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PT Kalbe's earnings, one of the primary drivers of an investment's value.About PT Kalbe Financial Statements
PT Kalbe stakeholders use historical fundamental indicators, such as PT Kalbe's revenue or net income, to determine how well the company is positioned to perform in the future. Although PT Kalbe investors may analyze each financial statement separately, they are all interrelated. For example, changes in PT Kalbe's assets and liabilities are reflected in the revenues and expenses on PT Kalbe's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in PT Kalbe Farma. Please read more on our technical analysis and fundamental analysis pages.
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia. PT Kalbe operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 12501 people.
Currently Active Assets on Macroaxis
Other Information on Investing in PTKFF Pink Sheet
PT Kalbe financial ratios help investors to determine whether PTKFF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PTKFF with respect to the benefits of owning PT Kalbe security.